QLT PhotoTherapeutics (QLTI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: George Mc Geary who wrote (922)	6/9/2000 1:48:00 PM
From: Ian@SI	Read Replies (1) of 1321

It is somewhat astounding that QLT drops $25+ after the FDA approval then gains it back after the Canadian approval. I suspect that the research done by Christine Charest and conference with the Retinal Specialists has firmly put to rest any doubts about Visudyne sales. In addition, Julia Levy was the guest Interviewee on a full segment of Prime Business last Monday. Among other encouraging statements, she confirmed that she's quite comfortable with analysts' estimates for QLT's first quarter of profitability [4th Q]. When asked about competitors, she stated that she believes QLT is at least 2 years ahead of the nearest competitor. (MRVT - they only filled their Ph III trial during 4Q99. With a 2 year study, plus time to unblind and analyze the data, then at least 6 months after submission to possibly get FDA approval, it's conceivable that QLT will have this market all to itself for up to 3 years.) So all in all, it seems that the analyst community and institutional investors are finally beginning to understand and believe that QLT has a major blockbuster all to themselves for at least a couple years if not much longer. Ian.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next